Rotigotine Impurity Detection Using Tetrahydro-Naphthol Reference Standard
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting impurities in rotigotine, a dopamine receptor agonist used to treat Parkinson's disease, are inadequate in ensuring drug quality and safety, as they fail to effectively monitor and control impurities introduced during production and storage, which can affect the drug's stability and efficacy.
Innovation Solution
A new reference compound, 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol, is developed and used as a standard for qualitative and quantitative analysis of impurities in rotigotine through high-pressure liquid chromatography (HPLC), allowing for the determination of impurity content and ensuring purity levels of at least 95%.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional impurity detection methods are used for rotigotine, then the detection process is simple, but the measurement precision and reliability of impurity determination are insufficient
Solution Approach 1:
The patent introduces a specific impurity compound (5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol) as a reference standard to serve as an intermediary for detecting and quantifying impurities in rotigotine. This reference compound enables precise identification and measurement of impurity levels through HPLC, directly resolving the contradiction by providing a mediator that enhances measurement precision without requiring complex analytical systems.
2Reliability
If conventional separation and detection conditions are used, then the analysis process is straightforward, but the ability to effectively separate and detect impurities is inadequate
Solution Approach 1:
The patent establishes predetermined HPLC separation and detection conditions specifically optimized for the reference compound before actual impurity analysis. By pre-establishing these conditions including mobile phase composition, flow rate, detection wavelength, and retention time parameters, the method ensures reliable and reproducible impurity detection without requiring complex real-time optimization, thus resolving the contradiction between reliability and detection difficulty.
3Ease of manufacture
If no specific reference compound is used, then the quality standard establishment is simpler, but the quality control and safety assurance of the drug is compromised
Solution Approach 1:
The patent changes the parameter of using a specific chemical structure (the reference compound with formula (I)) as the basis for quality standards. By defining specific physical and chemical parameters of this reference compound including purity specifications (≥95%), the patent establishes a concrete basis for quality control that enhances manufacturing precision while maintaining ease of standard establishment through clear, measurable parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The reference compound enables precise detection and quantification of impurities in rotigotine, enhancing the quality and safety of the drug by establishing reliable separation and detection conditions, thereby improving the management of impurities and ensuring the drug's stability and efficacy.
Implementation Method 1
HPLC chromatograms of the reference solution and the test solution are obtained by high pressure liquid chromatography analysis respectively
Data Source
AI summary
The present disclosure relates to 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol, a method for preparing the same, and use of 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol as a reference compound for determining an impurity in rotigotine or a preparation thereof.